Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1983 Mar;80(5):1459–1462. doi: 10.1073/pnas.80.5.1459

Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone.

T W Redding, A V Schally
PMCID: PMC393617  PMID: 6219395

Abstract

Experiments were undertaken with estrogen-dependent mammary carcinomas in rats and mice to determine the antitumor activities of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone (LH-RH). Chronic administration of the agonist [D-Trp6]LH-RH or of antagonist 1 ( [NAc-D-p-Cl-Phe1,2-Phe3,D-Arg6-D-Ala10]LH-RH) at doses of 25 and 50 micrograms/day, respectively, for 21 days to mice bearing the MXT mammary carcinoma significantly decreased tumor weight and volume. The weight of the ovaries and serum progesterone levels in mice treated with [D-Trp6]LH-RH or antagonist 1 were also significantly reduced. In rats bearing the MT/W9A mammary adenocarcinoma, chronic administration of [D-Trp6]LH-RH at a dose of 25 micrograms twice a day or of antagonist 2 ( [NAc-D-p-Cl-Phe1,2,D-Trp3,D-Arg6,D-Ala10]LH-RH) at a dose of 50 micrograms twice a day for 28 days significantly decreased tumor weight and volume. Chronic treatment with either [D-Trp6]LH-RH or antagonist 2 markedly diminished the weight of the ovaries and serum levels of both estrogen and progesterone. Serum luteinizing hormone was significantly decreased in rats treated with antagonist 2 but not in rats treated with [D-Trp6]LH-RH. There was a significant drop in serum prolactin levels in rats treated with [D-Trp6]LH-RH but not in those receiving antagonist 2. Regression of mammary tumors in rats and mice in response to chronic administration of [D-Trp6]LH-RH and the two antagonistic analogs of LH-RH suggests that these compounds should be considered for the development of a new hormone therapy for breast cancer in women.

Full text

PDF
1459

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arafah B. M., Manni A., Pearson O. H. Effect of hypophysectomy and hormone replacement of hormone receptor levels and the growth of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Endocrinology. 1980 Nov;107(5):1364–1369. doi: 10.1210/endo-107-5-1364. [DOI] [PubMed] [Google Scholar]
  2. Bex F. J., Corbin A., France E. Resistance of the mouse to the antifertility effects of LHRH agonists. Life Sci. 1982 Apr 12;30(15):1263–1269. doi: 10.1016/0024-3205(82)90688-9. [DOI] [PubMed] [Google Scholar]
  3. Coy D. H., Horvath A., Nekola M. V., Coy E. J., Erchegyi J., Schally A. V. Peptide antagonists of LH-RH: large increases in antiovulatory activities produced by basic D-amino acids in the six position. Endocrinology. 1982 Apr;110(4):1445–1447. doi: 10.1210/endo-110-4-1445. [DOI] [PubMed] [Google Scholar]
  4. Coy D. H., Vilchez-Martinez J. A., Coy E. J., Schally A. V. Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem. 1976 Mar;19(3):423–425. doi: 10.1021/jm00225a018. [DOI] [PubMed] [Google Scholar]
  5. DANIEL P. M., PRICHARD M. M. THE RESPONSE OF EXPERIMENTALLY INDUCED MAMMARY TUMOURS IN RATS TO HYPOPHYSECTOMY AND TO PITUITARY STALK SECTION. Br J Cancer. 1963 Sep;17:446–453. doi: 10.1038/bjc.1963.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Danguy A., Legros N., Heuson-Stiennon J. A., Pasteels J. L., Atassi G., Heuson J. C. Effects of a gonadotropin-releasing hormone (GnRH) analogue (A-43818) on 7, 12- dimethylbenz (a)anthracene-induced rat mammary tumors. Histological and endocrine studies. Eur J Cancer. 1977 Oct;13(10):1089–1094. doi: 10.1016/0014-2964(77)90005-6. [DOI] [PubMed] [Google Scholar]
  7. DeSombre E. R., Johnson E. S., White W. F. Regression of rat mammary tumors effected by a gonadoliberin analog. Cancer Res. 1976 Oct;36(10):3830–3833. [PubMed] [Google Scholar]
  8. Erchegyi J., Coy D. H., Nekola M. V., Coy E. J., Schally A. V., Mezo I., Teplan I. Luteinizing hormone-releasing hormone analogs with increased anti-ovulatory activity. Biochem Biophys Res Commun. 1981 Jun 16;100(3):915–920. doi: 10.1016/0006-291x(81)91910-0. [DOI] [PubMed] [Google Scholar]
  9. HUGGINS C., BRIZIARELLI G., SUTTON H., Jr Rapid induction of mammary carcinoma in the rat and the influence of hormones on the tumors. J Exp Med. 1959 Jan 1;109(1):25–42. doi: 10.1084/jem.109.1.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. HUGGINS C., MOON R. C., MORII S. Extinction of experimental mammary cancer. I. Estradiol-17beta and progesterone. Proc Natl Acad Sci U S A. 1962 Mar 15;48:379–386. doi: 10.1073/pnas.48.3.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Horwitz K. B., McGuire W. L. Progesterone and progesterone receptors in experimental breast cancer. Cancer Res. 1977 Jun;37(6):1733–1738. [PubMed] [Google Scholar]
  12. Hsueh A. J., Jones P. B. Extrapituitary actions of gonadotropin-releasing hormone. Endocr Rev. 1981 Fall;2(4):437–461. doi: 10.1210/edrv-2-4-437. [DOI] [PubMed] [Google Scholar]
  13. Jabara A. G. Effects of progesterone on 9,10-dimethyl-1,2-benzanthracene-induced mammary tumours in Sprague-Dawley rats. Br J Cancer. 1967 Jun;21(2):418–429. doi: 10.1038/bjc.1967.48. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Janik P., Briand P., Hartmann N. R. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res. 1975 Dec;35(12):3698–3704. [PubMed] [Google Scholar]
  15. Kim U., Depowski M. J. Progression from hormone dependence to autonomy in mammary tumors as an in vivo manifestation of sequential clonal selection. Cancer Res. 1975 Aug;35(8):2068–2077. [PubMed] [Google Scholar]
  16. Manni A., Trujillo J. E., Pearson O. H. Predominant role of prolactin in stimulating the growth of 7, 12-dimethylbenz(a)anthracene-induced rat mammary tumor. Cancer Res. 1977 Apr;37(4):1216–1219. [PubMed] [Google Scholar]
  17. McCormick G. M., 2nd Ovariectomy and postpartum growth of rat mammary tumors. Eur J Cancer. 1973 Oct;9(10):775–776. doi: 10.1016/0014-2964(73)90072-8. [DOI] [PubMed] [Google Scholar]
  18. Nicholson R. I., Golder M. P. The effect of synthetic anti-oestrogens on the growth and biochemistry of rat mammary tumours. Eur J Cancer. 1975 Aug;11(8):571–579. doi: 10.1016/0014-2964(75)90129-2. [DOI] [PubMed] [Google Scholar]
  19. Nicholson R. I., Maynard P. V. Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer. 1979 Mar;39(3):268–273. doi: 10.1038/bjc.1979.50. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Niswender G. D., Chen C. L., Midgley A. R., Jr, Meites J., Ellis S. Radioimmunoassay for rat prolactin. Proc Soc Exp Biol Med. 1969 Mar;130(3):793–797. doi: 10.3181/00379727-130-33657. [DOI] [PubMed] [Google Scholar]
  21. Niswender G. D., Midgley A. R., Jr, Monroe S. E., Reichert L. E., Jr Radioimmunoassay for rat luteinizing hormone with antiovine LH serum and ovine LH-131-I. Proc Soc Exp Biol Med. 1968 Jul;128(3):807–811. doi: 10.3181/00379727-128-33129. [DOI] [PubMed] [Google Scholar]
  22. Pearson O. H., Llerena O., Llerena L., Molina A., Butler T. Prolactin-dependent rat mammary cancer: a model for man? Trans Assoc Am Physicians. 1969;82:225–238. [PubMed] [Google Scholar]
  23. Rose D. P., Pruitt B. Modification of the effect of a gonadoliberin analog on 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by hormone replacement. Cancer Res. 1979 Oct;39(10):3968–3970. [PubMed] [Google Scholar]
  24. Schally A. V., Coy D. H., Arimura A. LH-RH agonists and antagonists. Int J Gynaecol Obstet. 1980;18(5):318–324. doi: 10.1002/j.1879-3479.1980.tb00507.x. [DOI] [PubMed] [Google Scholar]
  25. Seppälä M., Wahlström T. Identification of luteinizing hormone-releasing factor and alpha subunit of glycoprotein hormones in ductal carcinoma of the mammary gland. Int J Cancer. 1980 Sep 15;26(3):267–268. doi: 10.1002/ijc.2910260303. [DOI] [PubMed] [Google Scholar]
  26. Sharpe R. M. Cellular aspects of the inhibitory actions of LH-RH on the ovary and testis. J Reprod Fertil. 1982 Mar;64(2):517–527. doi: 10.1530/jrf.0.0640517. [DOI] [PubMed] [Google Scholar]
  27. Watson C., Medina D., Clark J. H. Estrogen receptor characterization in a transplantable mouse mammary tumor. Cancer Res. 1977 Sep;37(9):3344–3348. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES